Anixa Biosciences Croissance future

Future contrôle des critères 0/6

Anixa Biosciences devrait augmenter ses bénéfices et ses revenus de 9.5% et de 75.2% par an respectivement, tandis que le BPA devrait croître de croître de 24.4% par an.

Informations clés

9.5%

Taux de croissance des bénéfices

24.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	75.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	19 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Oct 06

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Apr 27

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Jan 13

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Sep 26

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Aug 15

Anixa to get additional US patent linked to breast cancer vaccine technology

Jul 21

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jun 13

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

May 11

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Feb 24

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Oct 28

Our First Look At Anixa Biosciences

Sep 23

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

Jun 12

OntoChem assigns Anixa covid-19 drug discovery project to MolGenie

May 07

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Jan 13

Anixa Biosciences, Cleveland Clinic in ovarian cancer vaccine pact

Dec 01

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ANIX - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
10/31/2027	N/A	-17	-16	-16	1
10/31/2026	N/A	-16	-16	-16	1
10/31/2025	N/A	-15	-15	-15	2
10/31/2024	N/A	-13	-46	-11	2
7/31/2024	N/A	-12	-8	-8	N/A
4/30/2024	N/A	-12	-7	-7	N/A
1/31/2024	0	-11	-7	-7	N/A
10/31/2023	0	-10	-6	-6	N/A
7/31/2023	0	-11	-6	-6	N/A
4/30/2023	0	-11	-6	-6	N/A
1/31/2023	N/A	-12	-7	-7	N/A
10/31/2022	N/A	-14	-6	-6	N/A
7/31/2022	0	-14	-6	-6	N/A
4/30/2022	0	-16	-6	-6	N/A
1/31/2022	0	-15	-5	-5	N/A
10/31/2021	1	-13	-5	-5	N/A
7/31/2021	1	-11	-5	-5	N/A
4/30/2021	1	-9	-5	-5	N/A
1/31/2021	1	-10	-5	-5	N/A
10/31/2020	N/A	-10	-6	-6	N/A
7/31/2020	N/A	-10	-6	-6	N/A
4/30/2020	N/A	-9	-5	-5	N/A
1/31/2020	0	-9	-6	-5	N/A
10/31/2019	0	-12	-5	-5	N/A
7/31/2019	0	-15	-5	-4	N/A
4/30/2019	1	-18	-5	-5	N/A
1/31/2019	1	-17	-4	-4	N/A
10/31/2018	1	-14	-4	-4	N/A
7/31/2018	1	-10	-4	-4	N/A
4/30/2018	1	-7	N/A	-4	N/A
1/31/2018	0	-5	N/A	-4	N/A
10/31/2017	0	-7	N/A	-4	N/A
7/31/2017	1	-6	N/A	-4	N/A
4/30/2017	0	-6	N/A	-3	N/A
1/31/2017	0	-7	N/A	-4	N/A
10/31/2016	0	-5	N/A	-3	N/A
7/31/2016	0	-5	N/A	-4	N/A
4/30/2016	0	-6	N/A	-3	N/A
1/31/2016	0	-7	N/A	-4	N/A
10/31/2015	0	-1	N/A	1	N/A
7/31/2015	2	-3	N/A	2	N/A
4/30/2015	3	-1	N/A	2	N/A
1/31/2015	4	-2	N/A	3	N/A
10/31/2014	4	-10	N/A	-2	N/A
7/31/2014	3	-9	N/A	-3	N/A
4/30/2014	1	-12	N/A	-3	N/A
1/31/2014	0	-12	N/A	-3	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ANIX devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ANIX devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ANIX devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: ANIX ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: ANIX ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ANIX devrait être élevé dans 3 ans

Anixa Biosciences Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 11% to US$10.50

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target increased to US$11.00

Consensus forecasts updated

Price target increased to US$9.00

Recent updates

Anixa Biosciences, Inc Initiates Dosing in Third Cohort in its Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting

Now 20% undervalued

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences, Inc. Announces Submission of Protocol Amendment for CAR-T Trial

New minor risk - Share price stability

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Lead Independent Director recently bought US$84k worth of stock

Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology

Anixa Biosciences, Inc. (NasdaqCM:ANIX) announces an Equity Buyback for $5 million worth of its shares.

Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

CEO, Chairman & Co-Chair of CBAB recently bought US$60k worth of stock

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc. Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

Anixa Biosciences Welcomes Sanjay Juneja to Its Cancer Business Advisory Board

CEO, Chairman & Co-Chair of CBAB recently bought US$97k worth of stock

New minor risk - Market cap size

New major risk - Revenue and earnings growth

Anixa Biosciences, Inc., Annual General Meeting, Mar 21, 2024

New minor risk - Share price stability

Anixa Biosciences, Inc. Announces Japanese Patent on Ovarian Cancer Vaccine Technology

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Anixa Biosciences, Inc. Appoints Mark A. Goldberg, Md, to Its Cancer Business Advisory Board

Anixa Biosciences, Inc. Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Anixa Biosciences, Inc. Establishes Cancer Business Advisory Board

Anixa Biosciences, Inc. Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial

Lead Independent Director exercised options to buy US$119k worth of stock.

Press Release: Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Now 38% undervalued after recent price drop

Price target increased by 11% to US$10.50

Anixa Biosciences, Inc., Annual General Meeting, Mar 09, 2023

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine

Insufficient new directors

Insufficient new directors

Anixa Biosciences Inc. Announces Commencement of Phase 1B Trial of Its Breast Cancer Vaccine At Cleveland Clinic

Lead Independent Director exercised options to buy US$197k worth of stock.

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Chairman & CEO exercised options and sold US$937k worth of stock

Anixa Biosciences Announces Treatment of First Patient in Its Ovarian Cancer Car-T Clinical Trial

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

Anixa to get additional US patent linked to breast cancer vaccine technology

Lead Independent Director exercised options to buy US$144k worth of stock.

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Price target increased to US$11.00

Anixa Biosciences, Inc. Announces Management Changes

Anixa Biosciences, Inc. Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences, Inc., Annual General Meeting, Mar 10, 2022

Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine

Anixa Biosciences and MolGenie Announce Early Potency Analysis of SARS-CoV-2 Protease Inhibitor

Chairman recently bought US$60k worth of stock

Anixa Biosciences and Molgenie Announce That Their Covid-19 Compounds Are Expected to Be Effective Against the Omicron Variant

Lead Independent Director recently bought US$87k worth of stock

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

Our First Look At Anixa Biosciences

Anixa Biosciences' Covid-19 Compounds Expected to Be Effective Against the Delta Variant

Anixa Biosciences, Inc. Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology